Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Multimedia Available: Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease

--(BUSINESS WIRE)--Most people with chronic kidney disease die from cardiovascular problems before ever receiving dialysis or a transplant. Now there's a new clinical trial called TREAT -- Trial To Reduce Cardiovascular Events with Aranesp Therapy. The goal of the trial is to determine if treating anemia will reduce cardiovascular events in people with chronic kidney disease and Type 2 diabetes.

Radio News Feature

You can reach the story directly by going to: http://www.newstream.com/home.aspx?story=30339

This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.

If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.

CONTACT: Newstream, New York

SOURCE: Newstream and Amgen